Angiotensin II induces interleukin-1b-mediated islet inflammation and β-cell dysfunction independently of vasoconstrictive effects

Diabetes

Volumn 64, Issue 4, 2015, Pages 1273-1283

  Sauter, Nadine S ^a,b   Thienel, Constanze ^a,b   Plutino, Yuliya ^a   Kampe, Kapil ^b   Dror, Erez ^a,b   Traub, Shuyang ^a,b   Timper, Katharina ^a,b   Bédat, Benoit ^c,d   Pattou, Francois ^e   Kerr Conte, Julie ^e   Jehle, Andreas W ^a,b   Böni Schnetzler, Marianne ^a,b   Donath, Marc Y ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^e UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; GLUCOSE; HYDRALAZINE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; GLUCOSE BLOOD LEVEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET BETA CELL DYSFUNCTION; PANCREAS ISLET DISEASE; PANCREAS ISLET INFLAMMATION; PANCREATITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASOCONSTRICTION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; INFLAMMATION; LIPID DIET; METABOLISM; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECRETION (PROCESS);

ANGIOTENSIN II; ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; HUMANS; INFLAMMATION; INSULIN; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MICE; MITOCHONDRIA; RENIN-ANGIOTENSIN SYSTEM; VASOCONSTRICTION;

EID: 84929504321     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1282     Document Type: Article

References (53)

1. Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res 2000;8: 337-341
2. Chu KY, Lau T, Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006;55: 367-374
3. Feng Y, Yue X, Xia H, et al. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res 2008;102: 729-736
4. Prisant LM. Preventing type II diabetes mellitus. J Clin Pharmacol 2004;44: 406-413
5. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23: 463-473
6. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821-826
7. Frantz ED, Crespo-Mascarenhas C, Barreto-Vianna AR, Aguila MB, Mandarim-de-Lacerda CA. Renin-angiotensin system blockers protect pancreatic islets against diet-induced obesity and insulin resistance in mice. PLoS One 2013;8: E67192
8. Shao J, Iwashita N, Ikeda F, et al. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem Biophys Res Commun 2006;344: 1224-1233
9. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004;53: 989-997
10. Yuan L, Li X, Xu GL, Qi CJ. Effects of renin-angiotensin system blockade on islet function in diabetic rats. J Endocrinol Invest 2010;33: 13-19
11. Peach MJ. Renin-angiotensin system: Biochemistry and mechanisms of action. Physiol Rev 1977;57: 313-370
12. Reams GP. Angiotensin-converting enzyme in renal and cerebral tissue and implications for successful blood pressure management. Am J Cardiol 1992;69: 59C-64C
13. Neri Serneri GG, Boddi M, Coppo M, et al. Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation 1996;94: 1886-1893
14. Karlsson C, Lindell K, Ottosson M, Sjöström L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998;83: 3925-3929
15. Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004;47: 240-248
16. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue reninangiotensin system in human pancreas. J Endocrinol 1999;161: 317-322
17. Lupi R, Del Guerra S, Bugliani M, et al. The direct effects of the angiotensinconverting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol 2006;154: 355-361
18. Frederich RC Jr, Kahn BB, Peach MJ, Flier JS. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992;19: 339-344
19. Jansson L. The regulation of pancreatic islet blood flow. Diabetes Metab Rev 1994;10: 407-416
20. Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41: 127-133
21. Ihoriya C, Satoh M, Kuwabara A, Sasaki T, Kashihara N. Angiotensin II regulates islet microcirculation and insulin secretion in mice. Microcirculation 2014;21: 112-123
22. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002;40: 872-879
23. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS. Angiotensin IIinduced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2008;294: E345-E351
24. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, Nunemaker CS. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010;55: 715-721
25. Zhang Z, Liu C, Gan Z, et al. Improved glucose-stimulated insulin secretion by selective intraislet inhibition of angiotensin II type 1 receptor expression in isolated islets of db/db mice. Int J Endocrinol 2013;2013: 319586
26. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24: 325-331
27. Böni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1βeta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008;93: 4065-4074
28. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007;56: 2356-2370
29. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356: 1517-1526
30. van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: A randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011;96: 2119-2126
31. Rissanen A, Howard CP, Botha J, Thuren T; Global Investigators. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: Results of a randomized, placebo-controlled trial. Diabetes Obes Metab 2012;14: 1088-1096
32. Sloan-Lancaster J, Abu-Raddad E, Polzer J, et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 2013;36: 2239-2246
33. Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012; 35: 1654-1662
34. Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1b antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab 2013;39: 524-531
35. Guo F, Chen XL, Wang F, Liang X, Sun YX, Wang YJ. Role of angiotensin II type 1 receptor in angiotensin II-induced cytokine production in macrophages. J Interferon Cytokine Res 2011;31: 351-361
36. Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 2002;3: 569-577
37. Ruiz-Ortega M, Ruperez M, Lorenzo O, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002;(82): S12-S22
38. Chehl N, Gong Q, Chipitsyna G, Aziz T, Yeo CJ, Arafat HA. Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells. J Gastrointest Surg 2009;13: 2189-2200
39. Schindler R, Dinarello CA, Koch KM. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 1995;7: 526-533
40. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005;46: 735-739
41. Fliser D, Schaefer F, Schmid D, Veldhuis JD, Ritz E. Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. Hypertension 1997;30: 1156-1161
42. Soejima H, Ogawa H, Yasue H, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999;34: 983-988
43. Yuan L, Li X, Li J, Li HL, Cheng SS. Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet. Acta Diabetol 2013;50: 479-488
44. Janjic D, Maechler P, Sekine N, Bartley C, Annen AS, Wolheim CB. Free radical modulation of insulin release in INS-1 cells exposed to alloxan. Biochem Pharmacol 1999;57: 639-648
45. Geiger T, Towbin H, Cosenti-Vargas A, et al. Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol 1993;11: 515-522
46. Weksler-Zangen S, Raz I, Lenzen S, et al. Impaired glucose-stimulated insulin secretion is coupled with exocrine pancreatic lesions in the Cohen diabetic rat. Diabetes 2008;57: 279-287
47. Sung YY, Lee YS, Jung WH, et al. Glucose intolerance in young TallyHo mice is induced by leptin-mediated inhibition of insulin secretion. Biochem Biophys Res Commun 2005;338: 1779-1787
48. Gletsu N, Doan TN, Cole J, Sutliff RL, Bernstein KE. Angiotensin II-induced hypertension in mice caused an increase in insulin secretion. Vascul Pharmacol 2005;42: 83-92
49. Maedler K, Schumann DM, Sauter N, et al. Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes 2006;55: 2713-2722
50. Spinas GA, Mandrup-Poulsen T, Mølvig J, et al. Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. Acta Endocrinol (Copenh) 1986;113: 551-558
51. Tsoporis J, Leenen FH. Effects of hydralazine on blood pressure, pressor mechanisms, and cardiac hypertrophy in two-kidney, one-clip hypertensive rats. Can J Physiol Pharmacol 1986;64: 1528-1534
52. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressorindependent mechanism. J Clin Invest 1996;97: 2509-2516
53. Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA. Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol 1998; 274: E867-E876